The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Open accessAbstract
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Self-citationDöhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationGenomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationSorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Self-citationAzacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
Self-citationMidostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Self-citationPadmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Self-citationEnasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
Self-citationDurable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716984 · Cited by 1,454
Self-citationGilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML
Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902688 · Cited by 1,287
Self-citationClonal hematopoiesis in human aging and disease
Jaiswal, S., & Ebert, B. L. (2019) · Science · doi:10.1126/science.aan4673 · Cited by 1,156
Self-citationLancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6112 · Cited by 1,025
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Self-citationAcute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
Self-citationRole of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892
Coombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.010 · Cited by 866
Self-citationAssessment of Minimal Residual Disease in Standard-Risk AML
Ivey, A., Hills, R. K., Simpson, M. A., Jovanovic, J. V., Gilkes, A., Grech, A., Patel, Y., Bhudia, N., Farah, H., Mason, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507471 · Cited by 845
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Jongen-Lavrencic, M., Grob, T., Hanekamp, D., Kavelaars, F. G., al Hinai, A., Zeilemaker, A., Erpelinck-Verschueren, C. A. J., Gradowska, P. L., Meijer, R., Cloos, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716863 · Cited by 786
Self-citationWei, A. H., Montesinos, P., Ivanov, V., DiNardo, C. D., Novak, J., Laribi, K., Kim, I., Stevens, D. A., Fiedler, W., Pagoni, M., et al. (2020) · Blood · doi:10.1182/blood.2020004856 · Cited by 763
Self-citationHeuser, M., Freeman, S. D., Ossenkoppele, G. J., Buccisano, F., Hourigan, C. S., Ngai, L. L., Tettero, J. M., Bachas, C., Baer, C., Béné, M.-C., et al. (2021) · Blood · doi:10.1182/blood.2021013626 · Cited by 763
Self-citationHills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Self-citationCurrent Use of and Trends in Hematopoietic Cell Transplantation in the United States
D'Souza, A., Fretham, C., Lee, S. J., Arora, M., Brunner, J., Chhabra, S., Devine, S., Eapen, M., Hamadani, M., Hari, P., et al. (2020) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2020.04.013 · Cited by 712
Rücker, F. G., Schlenk, R. F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2012) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 683
Self-citationDiNardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., et al. (2020) · Blood · doi:10.1182/blood.2019003988 · Cited by 679
Self-citationScott, B. L., Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7091 · Cited by 667
Sanz, M. A., Fenaux, P., Tallman, M. S., Estey, E. H., Löwenberg, B., Naoe, T., Lengfelder, E., Döhner, H., Burnett, A. K., Chen, S.-J., et al. (2019) · Blood · doi:10.1182/blood-2019-01-894980 · Cited by 664
Self-citationBurnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
Burchert, A., Bug, G., Fritz, L. V., Finke, J., Stelljes, M., Röllig, C., Wollmer, E., Wäsch, R., Bornhäuser, M., Berg, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03345 · Cited by 555
Self-citationIvosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia
Montesinos, P., Recher, C., Vives, S., Zarzycka, E., Wang, J., Bertani, G., Heuser, M., Calado, R. T., Schuh, A. C., Yeh, S.-P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117344 · Cited by 514
Self-citationPrognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., Van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., De Greef, G. E., Jacky, E., Van der Lelie, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 511
Self-citationCortes, J. E., Heidel, F. H., Hellmann, A., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Pollyea, D. A., DesJardins, P., Ottmann, O., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0312-9 · Cited by 496
Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487
Self-citationCortes, J. E., Khaled, S., Martinelli, G., Perl, A. E., Ganguly, S., Russell, N., Krämer, A., Dombret, H., Hogge, D., Jonas, B. A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30150-0 · Cited by 485
Self-citationMcMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1453 · Cited by 446
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Wei, A. H., Döhner, H., Pocock, C., Montesinos, P., Afanasyev, B., Dombret, H., Ravandi, F., Sayar, H., Jang, J.-H., Porkka, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004444 · Cited by 445
Self-citationCord-Blood Transplantation in Patients with Minimal Residual Disease
Milano, F., Gooley, T., Wood, B., Woolfrey, A., Flowers, M. E., Doney, K., Witherspoon, R., Mielcarek, M., Deeg, J. H., Sorror, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602074 · Cited by 443
Self-citationTerwijn, M., van Putten, W. L. J., Kelder, A., van der Velden, V. H. J., Brooimans, R. A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G. E., Valk, P. J. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9628 · Cited by 442
Self-citationHourigan, C. S., Dillon, L. W., Gui, G., Logan, B. R., Fei, M., Ghannam, J., Li, Y., Licon, A., Alyea, E. P., Bashey, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03011 · Cited by 442
Sorror, M. L., Storb, R. F., Sandmaier, B. M., Maziarz, R. T., Pulsipher, M. A., Maris, M. B., Bhatia, S., Ostronoff, F., Deeg, H. J., Syrjala, K. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8157 · Cited by 423
Self-citationTherapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Le Beau, M. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.60 · Cited by 419
Self-citationBurnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A. E., Yin, J., Craddock, C. F., Dufva, I. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2964 · Cited by 409
Self-citationCytarabine Dose for Acute Myeloid Leukemia
Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Biemond, B. J., Gratwohl, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010222 · Cited by 407
Self-citationShort, N. J., Zhou, S., Fu, C., Berry, D. A., Walter, R. B., Freeman, S. D., Hourigan, C. S., Huang, X., Nogueras Gonzalez, G., Hwang, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4600 · Cited by 390
A disease risk index for patients undergoing allogeneic stem cell transplantation
Armand, P., Gibson, C. J., Cutler, C., Ho, V. T., Koreth, J., Alyea, E. P., Ritz, J., Sorror, M. L., Lee, S. J., Deeg, H. J., et al. (2012) · Blood · doi:10.1182/blood-2012-03-418202 · Cited by 384
Self-citationRoboz, G. J., DiNardo, C. D., Stein, E. M., de Botton, S., Mims, A. S., Prince, G. T., Altman, J. K., Arellano, M. L., Donnellan, W., Erba, H. P., et al. (2020) · Blood · doi:10.1182/blood.2019002140 · Cited by 381
Self-citationStyczynski, J., Reusser, P., Einsele, H., de la Camara, R., Cordonnier, C., Ward, K. N., Ljungman, P., Engelhard, D., & Leukemia, F. T. E. C. O. I. I. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.386 · Cited by 380
Lambert, J., Pautas, C., Terré, C., Raffoux, E., Turlure, P., Caillot, D., Legrand, O., Thomas, X., Gardin, C., Gogat-Marchant, K., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.188888 · Cited by 361
Self-citationMaertens, J. A., Girmenia, C., Brüggemann, R. J., Duarte, R. F., Kibbler, C. C., Ljungman, P., Racil, Z., Ribaud, P., Slavin, M. A., Cornely, O. A., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky286 · Cited by 348
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Cornelissen, J. J., & Blaise, D. (2016) · Blood · doi:10.1182/blood-2015-07-604546 · Cited by 346
Stein, E. M., DiNardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., Roboz, G. J., Patel, M. R., Collins, R., Flinn, I. W., et al. (2019) · Blood · doi:10.1182/blood-2018-08-869008 · Cited by 331
Self-citationXuan, L., Wang, Y., Huang, F., Fan, Z., Xu, Y., Sun, J., Xu, N., Deng, L., Li, X., Liang, X., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30455-1 · Cited by 329
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Uy, G. L., Aldoss, I., Foster, M. C., Sayre, P. H., Wieduwilt, M. J., Advani, A. S., Godwin, J. E., Arellano, M. L., Sweet, K. L., Emadi, A., et al. (2021) · Blood · doi:10.1182/blood.2020007732 · Cited by 326
Self-citationDehn, J., Spellman, S., Hurley, C. K., Shaw, B. E., Barker, J. N., Burns, L. J., Confer, D. L., Eapen, M., Fernandez-Vina, M., Hartzman, R., et al. (2019) · Blood · doi:10.1182/blood.2019001212 · Cited by 323
Pollyea, D. A., Bixby, D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., de Lima, M., Fathi, A. T., Foran, J. M., Gojo, I., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0002 · Cited by 320
Self-citationGrob, T., Al Hinai, A. S. A., Sanders, M. A., Kavelaars, F. G., Rijken, M., Gradowska, P. L., Biemond, B. J., Breems, D. A., Maertens, J., van Marwijk Kooy, M., et al. (2022) · Blood · doi:10.1182/blood.2021014472 · Cited by 305
Self-citationBalsat, M., Renneville, A., Thomas, X., de Botton, S., Caillot, D., Marceau, A., Lemasle, E., Marolleau, J.-P., Nibourel, O., Berthon, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1875 · Cited by 303
Self-citationTowards precision medicine for AML
Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 301
Self-citationHow I treat acute myeloid leukemia in the era of new drugs
DiNardo, C. D., & Wei, A. H. (2020) · Blood · doi:10.1182/blood.2019001239 · Cited by 290
Self-citationMcDonald, G. B., Sandmaier, B. M., Mielcarek, M., Sorror, M., Pergam, S. A., Cheng, G.-S., Hingorani, S., Boeckh, M., Flowers, M. D., Lee, S. J., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-2936 · Cited by 285
Self-citationAcquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Intlekofer, A. M., Shih, A. H., Wang, B., Nazir, A., Rustenburg, A. S., Albanese, S. K., Patel, M., Famulare, C., Correa, F. M., Takemoto, N., et al. (2018) · Nature · doi:10.1038/s41586-018-0251-7 · Cited by 281
Self-citationLugthart, S., Gröschel, S., Beverloo, H. B., Kayser, S., Valk, P. J. M., van Zelderen-Bhola, S. L., Jan Ossenkoppele, G., Vellenga, E., van den Berg-de Ruiter, E., Schanz, U., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2771 · Cited by 256
Self-citationNiederwieser, D., Baldomero, H., Bazuaye, N., Bupp, C., Chaudhri, N., Corbacioglu, S., Elhaddad, A., Frutos, C., Galeano, S., Hamad, N., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279189 · Cited by 252
Self-citationKasamon, Y. L., Bolaños-Meade, J., Prince, G. T., Tsai, H.-L., McCurdy, S. R., Kanakry, J. A., Rosner, G. L., Brodsky, R. A., Perica, K., Smith, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4777 · Cited by 239
Agarwal, S. K., DiNardo, C. D., Potluri, J., Dunbar, M., Kantarjian, H. M., Humerickhouse, R. A., Wong, S. L., Menon, R. M., Konopleva, M. Y., & Salem, A. H. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.003 · Cited by 237
Self-citationLancet, J. E., Uy, G. L., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., Bixby, D. L., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00134-4 · Cited by 230
Estey, E., Thall, P., Beran, M., Kantarjian, H., Pierce, S., & Keating, M. (1997) · Blood · doi:10.1182/blood.v90.8.2969 · Cited by 229
Harding, J. J., Lowery, M. A., Shih, A. H., Schvartzman, J. M., Hou, S., Famulare, C., Patel, M., Roshal, M., Do, R. K., Zehir, A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0877 · Cited by 223
Self-citationVenditti, A., Piciocchi, A., Candoni, A., Melillo, L., Calafiore, V., Cairoli, R., de Fabritiis, P., Storti, G., Salutari, P., Lanza, F., et al. (2019) · Blood · doi:10.1182/blood.2018886960 · Cited by 220
Oran, B., de Lima, M., Garcia-Manero, G., Thall, P. F., Lin, R., Popat, U., Alousi, A. M., Hosing, C., Giralt, S., Rondon, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002544 · Cited by 219
Walter, R. B., Gyurkocza, B., Storer, B. E., Godwin, C. D., Pagel, J. M., Buckley, S. A., Sorror, M. L., Wood, B. L., Storb, R., Appelbaum, F. R., et al. (2015) · Leukemia · doi:10.1038/leu.2014.173 · Cited by 216
Self-citationon behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation), Ullmann, A. J., Schmidt-Hieber, M., Bertz, H., Heinz, W. J., Kiehl, M., Krüger, W., Mousset, S., Neuburger, S., Neumann, S., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2711-1 · Cited by 212
CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Zeijlemaker, W., Grob, T., Meijer, R., Hanekamp, D., Kelder, A., Carbaat-Ham, J. C., Oussoren-Brockhoff, Y. J. M., Snel, A. N., Veldhuizen, D., Scholten, W. J., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0326-3 · Cited by 212
Self-citationGarcia-Manero, G., Griffiths, E. A., Steensma, D. P., Roboz, G. J., Wells, R., McCloskey, J., Odenike, O., DeZern, A. E., Yee, K., Busque, L., et al. (2020) · Blood · doi:10.1182/blood.2019004143 · Cited by 210
Freeman, S. D., Hills, R. K., Virgo, P., Khan, N., Couzens, S., Dillon, R., Gilkes, A., Upton, L., Nielsen, O. J., Cavenagh, J. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.3425 · Cited by 201
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
Weinberg, O. K., Siddon, A., Madanat, Y. F., Gagan, J., Arber, D. A., Dal Cin, P., Narayanan, D., Ouseph, M. M., Kurzer, J. H., & Hasserjian, R. P. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006239 · Cited by 200
Self-citationWood, B., Jevremovic, D., Béné, M. C., Yan, M., Jacobs, P., Litwin, V., & ; on behalf of ICSH/ICCS Working Group (2013) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21108 · Cited by 199
Morton, L. M., Dores, G. M., Schonfeld, S. J., Linet, M. S., Sigel, B. S., Lam, C. J. K., Tucker, M. A., & Curtis, R. E. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5625 · Cited by 199
Döhner, K., Thiede, C., Jahn, N., Panina, E., Gambietz, A., Larson, R. A., Prior, T. W., Marcucci, G., Jones, D., Krauter, J., et al. (2020) · Blood · doi:10.1182/blood.2019002697 · Cited by 197
Self-citationFathi, A. T., DiNardo, C. D., Kline, I., Kenvin, L., Gupta, I., Attar, E. C., Stein, E. M., de Botton, S., & for the AG221-C-001 Study Investigators (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4695 · Cited by 195
Self-citationBurd, A., Levine, R. L., Ruppert, A. S., Mims, A. S., Borate, U., Stein, E. M., Patel, P., Baer, M. R., Stock, W., Deininger, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1089-8 · Cited by 185
Self-citationDistinguishing AML from MDS: a fixed blast percentage may no longer be optimal
Estey, E. H., Hasserjian, R. P., & Döhner, H. (2021) · Blood · doi:10.1182/blood.2021011304 · Cited by 180
Self-citationMaiti, A., Rausch, C. R., Cortes, J. E., Pemmaraju, N., Daver, N. G., Ravandi, F., Garcia-Manero, G., Borthakur, G., Naqvi, K., Ohanian, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.252569 · Cited by 179
Self-citationShort, N. J., Montalban-Bravo, G., Hwang, H., Ning, J., Franquiz, M. J., Kanagal-Shamanna, R., Patel, K. P., DiNardo, C. D., Ravandi, F., Garcia-Manero, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003120 · Cited by 179
Self-citationPratz, K. W., Jonas, B. A., Pullarkat, V., Recher, C., Schuh, A. C., Thirman, M. J., Garcia, J. S., DiNardo, C. D., Vorobyev, V., Fracchiolla, N. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01546 · Cited by 179
Self-citationAzacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
Huls, G., Chitu, D. A., Havelange, V., Jongen-Lavrencic, M., van de Loosdrecht, A. A., Biemond, B. J., Sinnige, H., Hodossy, B., Graux, C., Kooy, R. V. M., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879866 · Cited by 177
Self-citationClonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
Schmalbrock, L. K., Dolnik, A., Cocciardi, S., Sträng, E., Theis, F., Jahn, N., Panina, E., Blätte, T. J., Herzig, J., Skambraks, S., et al. (2021) · Blood · doi:10.1182/blood.2020007626 · Cited by 174
Self-citationChurpek, J. E., Marquez, R., Neistadt, B., Claussen, K., Lee, M. K., Churpek, M. M., Huo, D., Weiner, H., Bannerjee, M., Godley, L. A., et al. (2016) · Cancer · doi:10.1002/cncr.29615 · Cited by 169
Self-citationDonor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
Gibson, C. J., Kim, H. T., Zhao, L., Murdock, H. M., Hambley, B., Ogata, A., Madero-Marroquin, R., Wang, S., Green, L., Fleharty, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02286 · Cited by 168
Gooptu, M., Romee, R., St. Martin, A., Arora, M., Al Malki, M., Antin, J. H., Bredeson, C. N., Brunstein, C. G., Chhabra, S., Fuchs, E. J., et al. (2021) · Blood · doi:10.1182/blood.2021011281 · Cited by 168
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2012-07-444851 · Cited by 165
Self-citationWermke, M., Kraus, S., Ehninger, A., Bargou, R. C., Goebeler, M.-E., Middeke, J. M., Kreissig, C., von Bonin, M., Koedam, J., Pehl, M., et al. (2021) · Blood · doi:10.1182/blood.2020009759 · Cited by 165
Lim, W.-S., Tardi, P. G., Dos Santos, N., Xie, X., Fan, M., Liboiron, B. D., Huang, X., Harasym, T. O., Bermudes, D., & Mayer, L. D. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.01.015 · Cited by 164
Kharfan-Dabaja, M. A., Labopin, M., Polge, E., Nishihori, T., Bazarbachi, A., Finke, J., Stadler, M., Ehninger, G., Lioure, B., Schaap, N., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2091 · Cited by 162
Taube, F., Georgi, J. A., Kramer, M., Stasik, S., Middeke, J. M., Röllig, C., Krug, U., Krämer, A., Scholl, S., Hochhaus, A., et al. (2022) · Blood · doi:10.1182/blood.2020009680 · Cited by 162
Self-citationShouval, R., Bondi, O., Mishan‐Shamay, H., Shimoni, A., Unger, R., & Nagler, A. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.146 · Cited by 161
Craddock, C., Jackson, A., Loke, J., Siddique, S., Hodgkinson, A., Mason, J., Andrew, G., Nagra, S., Malladi, R., Peniket, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02308 · Cited by 160
Self-citationGanzel, C., Sun, Z., Cripe, L. D., Fernandez, H. F., Douer, D., Rowe, J. M., Paietta, E. M., Ketterling, R. P., O’Connell, M. J., Wiernik, P. H., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25162 · Cited by 159
Self-citationPerl, A. E., Larson, R. A., Podoltsev, N. A., Strickland, S. A., Wang, E. S., Atallah, E. L., Schiller, G. J., Martinelli, G., Neubauer, A., Sierra, J., et al. (2022) · Blood · doi:10.1182/blood.2021011583 · Cited by 158
Self-citationLeukemic stem cells: identification and clinical application
Hanekamp, D., Cloos, J. J., & Schuurhuis, G. J. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2221-5 · Cited by 145
de Botton, S., Montesinos, P., Schuh, A. C., Papayannidis, C., Vyas, P., Wei, A. H., Ommen, H. B., Семочкин, С. В., Kim, H., Larson, R. A., et al. (2022) · Blood · doi:10.1182/blood.2021014901 · Cited by 143
Self-citationCraddock, C., Labopin, M., Robin, M., Finke, J., Chevallier, P., Yakoub‐Agha, I., Bourhis, J. H., Sengeløv, H., Blaise, D., Luft, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140996 · Cited by 142
Self-citationRöllig, C., Krämer, M., Schliemann, C., Mikesch, J., Steffen, B., Krämer, A., Noppeney, R., Schäfer‐Eckart, K., Krause, S. W., Hänel, M., et al. (2020) · Blood · doi:10.1182/blood.2019004583 · Cited by 140
Self-citationMiesner, M., Haferlach, C., Bacher, U., Weiss, T., Macijewski, K., Kohlmann, A., Klein, H., Dugas, M., Kern, W., Schnittger, S., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279794 · Cited by 129
Rücker, F. G., Agrawal, M., Corbacioglu, A., Weber, D., Kapp‐Schwoerer, S., Gaidzik, V. I., Jahn, N., Schroeder, T. A., Wattad, M. A., Lübbert, M., et al. (2019) · Blood · doi:10.1182/blood.2019001425 · Cited by 128
Self-citationLoke, J. C. T., Malladi, R. K., Moss, P. A. H., & Craddock, C. (2019) · British Journal of Haematology · doi:10.1111/bjh.16355 · Cited by 127
Self-citationTarlock, K., Lamble, A. J., Wang, Y., Gerbing, R. B., Ries, R. E., Loken, M. R., Brodersen, L. E., Pardo, L. M., Leonti, A. R., Smith, J. L., et al. (2021) · Blood · doi:10.1182/blood.2020009652 · Cited by 126
Ok, C. Y., Patel, K. P., Garcia‐Manero, G., Routbort, M. J., Fu, B., Tang, G., Goswami, M., Singh, R. R., Kanagal‐Shamanna, R., Pierce, S. A., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.12.006 · Cited by 125
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
Loke, J. C. T., Buka, R. J., & Craddock, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.659595 · Cited by 124
Self-citationClonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
Hasserjian, R. P., Steensma, D. P., Graubert, T. A., & Ebert, B. L. (2020) · Blood · doi:10.1182/blood.2019004770 · Cited by 122
Self-citationKröger, N. M., Brand, R., van Biezen, A., Zander, A., Dierlamm, J., Niederwieser, D. W., Devergié, A., Ruutu, T., Cornish, J., Ljungman, P. T., et al. (2009) · Haematologica · doi:10.3324/haematol.2008.000927 · Cited by 121
Self-citationKapp‐Schwoerer, S., Weber, D., Corbacioglu, A., Gaidzik, V. I., Paschka, P., Krönke, J., Theis, F., Rücker, F. G., Teleanu, M., Panina, E., et al. (2020) · Blood · doi:10.1182/blood.2020005998 · Cited by 119
Self-citationBewersdorf, J. P., & Zeidan, A. M. (2020) · Cells · doi:10.3390/cells9102310 · Cited by 119
Heuser, M., Heida, B., Büttner, K., Wienecke, C. P., Teich, K., Funke, C., Brandes, M., Klement, P., Liebich, A., Wichmann, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004367 · Cited by 119
Self-citationPrognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
Wakita, S., Sakaguchi, M., Oh, I., Kako, S., Toya, T., Najima, Y., Doki, N., Kanda, J., Kuroda, J., Mori, S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004292 · Cited by 117
Angenendt, L., Röllig, C., Montesinos, P., Martínez‐Cuadrón, D., Barragán, E., García, R., Botella, C., Martı́nez, P., Ravandi, F., Kadia, T. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00416 · Cited by 116
Self-citationSchlenk, R. F., Paschka, P., Krzykalla, J., Weber, D., Kapp‐Schwoerer, S., Gaidzik, V. I., Leis, C., Fiedler, W., Kindler, T., Schroeder, T. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01406 · Cited by 115
Self-citationSchulz, E., Valentin, A., Ulz, P., Beham‐Schmid, C., LIND, K., Rupp, V., Lackner, H., Wölfler, A., Zebisch, A., Olipitz, W., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100674 · Cited by 113
Bravo, G. M., Kanagal‐Shamanna, R., Sasaki, K., Patel, K. P., Gañán‐Gómez, I., Jabbour, E. J., Kadia, T. M., Ravandi, F., Dinardo, C. D., Borthakur, G., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026989 · Cited by 113
Self-citationYang, F., Long, N., Anekpuritanang, T., Bottomly, D., Savage, J. C., Lee, T. L., Solis-Ruiz, J. M., Borate, U., Wilmot, B., Tognon, C. E., et al. (2021) · Blood · doi:10.1182/blood.2021011354 · Cited by 111
Üstün, C., Le‐Rademacher, J. G., Wang, H.-L., Othus, M. K. D., Sun, Z., Major, B. T., Zhang, M., Storrick, E. M., Lafky, J. M., Chow, S. L.-M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0477-x · Cited by 109
Self-citationZeidan, A. M., DeAngelo, D. J., Palmer, J. M., Seet, C. S., Tallman, M. S., Wei, X., Raymon, H. K., Sriraman, P., Kopytek, S., Bewersdorf, J. P., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-021-04734-2 · Cited by 109
Self-citationLarson, R. A., Mandrekar, S. J., Huebner, L. J., Sanford, B. L., Laumann, K. M., Geyer, S. M., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01179-4 · Cited by 108
Self-citationEngelhard, D., Mohty, B., de la Cámara, R., Cordonnier, C., & Ljungman, P. T. (2013) · Transplant Infectious Disease · doi:10.1111/tid.12054 · Cited by 107
Stahl, M. F., Shallis, R. M., Wei, W., Montesinos, P., Lengliné, É., Neukirchen, J., Bhatt, V. R., Sekeres, M. A., Fathi, A. T., Koenig, H., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0783-3 · Cited by 107
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma
Swisher, E. M., Harrell, M. I., Norquist, B. M., Walsh, T., Brady, M. F., Lee, M. J., Hershberg, R. M., Kalli, K. R., Lankes, H. A., Konnick, E. Q., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6053 · Cited by 105
Middeke, J. M., Herold, S., Rücker‐Braun, E., Berdel, W. E., Stelljes, M., Kaufmann, M., Schäfer‐Eckart, K., Baldus, C. D., Stuhlmann, R., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13912 · Cited by 101
Self-citationDholaria, B., Savani, B. N., Hamilton, B. K., Oran, B., Liu, H. D., Tallman, M. S., Ciurea, S. O., Holtzman, N. G., Phillips, G. L., Devine, S. M., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.09.020 · Cited by 98
Self-citationSchmid, C., Labopin, M., Schaap, N. P., Veelken, H., Brecht, A., Stadler, M., Finke, J., Baron, F., Collin, M. P., Bug, G., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01515-3 · Cited by 98
Clinical Implications of Inflammation in Acute Myeloid Leukemia
Récher, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.623952 · Cited by 96
Ferguson, P., Hills, R. K., Grech, A., Betteridge, S., Kjeldsen, L., Dennis, M. W., Vyas, P., Goldstone, A. H., Milligan, D. W., Clark, R. E., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.148825 · Cited by 94
Self-citationMaiti, A., Dinardo, C. D., Wang, S. A., Jorgensen, J. L., Kadia, T. M., Daver, N. G., Short, N. J., Yilmaz, M. E., Pemmaraju, N., Borthakur, G. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003717 · Cited by 92
Self-citationGardin, C., Pautas, C., Fournier, É., Itzykson, R., Lemasle, É., Bourhis, J.-H., Adès, L., Marolleau, J., Malfuson, J., Gastaud, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001349 · Cited by 91
Self-citationAwada, H. K., Durmaz, A., Gurnari, C., Kishtagari, A., Meggendorfer, M., Kerr, C. M., Kuzmanovic, T., Durrani, J., Shreve, J. T., Nagata, Y., et al. (2021) · Blood · doi:10.1182/blood.2020010603 · Cited by 90
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
Paras, G., Morsink, L. M., Othus, M. K. D., Milano, F., Sandmaier, B. M., Zarling, L. C., Palmieri, R., Schoch, G. H., Davis, C., Bleakley, M., et al. (2022) · Blood · doi:10.1182/blood.2021014804 · Cited by 88
Self-citationWalter, R. B., Ofran, Y., Wierzbowska, A., Ravandi, F., Hourigan, C. S., Ngai, L. L., Venditti, A., Buccisano, F., Ossenkoppele, G. J., & Roboz, G. J. (2021) · Leukemia · doi:10.1038/s41375-021-01230-4 · Cited by 86
Self-citationDöhner, H., Weber, D., Krzykalla, J., Fiedler, W., Wulf, G. G., Salih, H. R., Lübbert, M., Kühn, M. W. M., Schroeder, T. A., Salwender, H. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007223 · Cited by 86
Self-citationRogers, H. J., Vardiman, J. W., Anastasi, J., Raca, G., Savage, N. M., Cherry, A. M., Arber, D. A., Moore, E. M., Morrissette, J. J. D., Bagg, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.096420 · Cited by 84
Self-citationOmmen, H. B. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715614529 · Cited by 84
More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia
Bravo, G. M., Benton, C. B., Wang, S. A., Ravandi, F., Kadia, T. M., Cortes, J. E., Daver, N. G., Takahashi, K., Dinardo, C. D., Jabbour, E. J., et al. (2017) · Blood · doi:10.1182/blood-2016-11-749903 · Cited by 84
Self-citationAtypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia
Ottema, S., Mulet‐Lazaro, R., Beverloo, H. B., Erpelinck-Verschueren, C. A. J., van Herk, S., van der Helm, R. M., Havermans, M., Grob, T., Valk, P. J. M., Bindels, E. M., et al. (2020) · Blood · doi:10.1182/blood.2019003701 · Cited by 82
Bravo, G. M., Kanagal‐Shamanna, R., Class, C. A., Sasaki, K., Ravandi, F., Cortes, J. E., Daver, N. G., Takahashi, K., Short, N. J., Dinardo, C. D., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25769 · Cited by 73
Self-citationThe acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms
Schwartz, J. R., Ma, J., Kamens, J. L., Westover, T., Walsh, M. P., Brady, S. W., Michael, J. R., Chen, X., Montefiori, L. E., Song, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21255-8 · Cited by 73
Woolfrey, A. E., Lee, S. J., Gooley, T. A., Malkki, M., Martin, P. J., Pagel, J. M., Hansen, J. A., & Petersdorf, E. W. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.03.024 · Cited by 70
Dinardo, C. D., Garcia‐Manero, G., Pierce, S. A., Nazha, A., Bueso-Ramos, C., Jabbour, E. J., Ravandi, F., Cortes, J. E., & Kantarjian, H. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24252 · Cited by 70
Self-citationClinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Patel, S. S., Ho, C., Ptashkin, R. N., Sadigh, S., Bagg, A., Geyer, J. T., Xu, M. L., Prébet, T., Mason, E. F., Seegmiller, A. C., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000090 · Cited by 70
Self-citationArber, D. A., Hasserjian, R. P., Orazi, A., Mathews, V., Roberts, A. W., Schiffer, C. A., Roug, A. S., Cazzola, M., Döhner, H., & Tefferi, A. (2022) · American Journal of Hematology · doi:10.1002/ajh.26503 · Cited by 69
Self-citationQin, N., Wang, Z., Liu, Q., Song, N., Wilson, C. L., Ehrhardt, M. J., Shelton, K., Easton, J. B., Mulder, H. L., Kennetz, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02760 · Cited by 67
Jaramillo, S., Benner, A., Krauter, J., Martin, H., Kindler, T., Bentz, M., Salih, H. R., Held, G., Köhne, C.-H., Götze, K. S. S., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.45 · Cited by 60
Self-citationWhat’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms
Voso, M. T., Falconi, G., & Fabiani, E. (2021) · Blood · doi:10.1182/blood.2021010764 · Cited by 60
Duhoux, F. P., Ameye, G., Montano‐Almendras, C. P., Bahloula, K., Mozziconacci, M. J., Laibe, S., Wlodarska, I., Michaux, L., Talmant, P., Richebourg, S., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08918.x · Cited by 56
van der Werf, I. M., Wojtuszkiewicz, A., Meggendorfer, M., Hütter, S., Baer, C. R., Heymans, M. W., Valk, P. J. M., Kern, W., Haferlach, C., Janssen, J. J. W. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004556 · Cited by 54
Self-citationNext‐generation sequencing for measurable residual disease detection in acute myeloid leukaemia
Ghannam, J. Y., Dillon, L. W., & Hourigan, C. S. (2019) · British Journal of Haematology · doi:10.1111/bjh.16362 · Cited by 53
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)
Dillon, R. J., Potter, N. E., Freeman, S. D., & Russell, N. H. (2020) · British Journal of Haematology · doi:10.1111/bjh.17185 · Cited by 53
Barker, J. N., Devlin, S. M., Naputo, K. A., Skinner, K., Maloy, M., Flynn, L., Anagnostou, T., Avecilla, S. T., Scaradavou, A., Cho, C., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003371 · Cited by 52
Soerensen, J. F., Aggerholm, A., Kerndrup, G. B., Hansen, M. H., Ewald, I. K. L., Bill, M., Ebbesen, L. H., Rosenberg, C. A., Hokland, P., Ludvigsen, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001157 · Cited by 51
Ok, C. Y., Hasserjian, R. P., Fox, P. S., et al. (2013) · Leukemia · doi:10.1038/leu.2013.191 · Cited by 50
Self-citationPPM1DMosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations
Pharoah, P. D. P., Song, H., Dicks, E., Intermaggio, M. P., Harrington, P. A., Baynes, C., Alsop, K., Chenevix‐Trench, G., Bogdanova, N. V., Cicek, M. S., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv347 · Cited by 50
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
Cappelli, L. V., Meggendorfer, M., Baer, C. R., Nadarajah, N., Hütter, S., Jeromin, S., Dicker, F., Kern, W., Haferlach, T., Haferlach, C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01368-1 · Cited by 50
Hereditary myeloid malignancies
Rafei, H., & Dinardo, C. D. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.001 · Cited by 49
Self-citationCui, W., Sun, J., Cotta, C. V., Medeiros, L. J., & Lin, P. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcp48ajdckthuxc · Cited by 48
Haferlach, C., Bacher, U., Haferlach, T., Dicker, F., Alpermann, T., Kern, W., & Schnittger, S. (2011) · Leukemia · doi:10.1038/leu.2011.5 · Cited by 46
Management of Disseminated Intravascular Coagulation in Acute Leukemias
Cate, H. T., & Leader, A. (2021) · Hämostaseologie · doi:10.1055/a-1393-8302 · Cited by 46
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Forghieri, F., Nasillo, V., Paolini, A., Bettelli, F., Pioli, V., Giusti, D., Gilioli, A., Colasante, C., Acquaviva, G., Riva, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238975 · Cited by 42
Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?
Potdar, R. R., Varadi, G., Fein, J. A., Labopin, M., Nagler, A., & Shouval, R. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.07.028 · Cited by 41
Jentzsch, M., Grimm, J., Bill, M., Brauer, D., Backhaus, D., Goldmann, K., Schulz, J. C., Niederwieser, D. W., Platzbecker, U., & Schwind, S. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01129-1 · Cited by 40
Self-citationKäyser, S., Hills, R. K., Langova, R., Krämer, M., Guijarro, F., Šustková, Z., Estey, E. H., Shaw, C. M., Ráčil, Z., Mayer, J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17336 · Cited by 38
Self-citationNorsworthy, K. J., Gao, X., Ko, C., Pulte, D. D., Zhou, J., Gong, Y. U. T., Shen, Y. L., Vallejo, J. J., Gwise, T. E., Sridhara, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01548 · Cited by 38
Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
Vonk, C. M., Hinai, A. S. A. A., Hanekamp, D., & Valk, P. J. M. (2021) · Cancers · doi:10.3390/cancers13215431 · Cited by 37
Acute Myeloid Leukemia With Recurrent Cytogenetic Abnormalities
Foucar, K. K., & Anastasi, J. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpi9c8uilyqtns · Cited by 35
Weinberg, O. K., Gibson, C. J., Blonquist, T. M., Neuberg, D. S., Pozdnyakova, O., Kuo, F. C., Ebert, B. L., & Hasserjian, R. P. (2018) · Haematologica · doi:10.3324/haematol.2017.181842 · Cited by 34
Self-citationInherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology
Roloff, G. W., Drazer, M. W., & Godley, L. A. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00387 · Cited by 33
Self-citationTrottier, A. M., & Godley, L. A. (2020) · British Journal of Haematology · doi:10.1111/bjh.17247 · Cited by 31
Self-citationRichardson, D. R., Swoboda, D. M., Moore, D. T., Johnson, S. M., Chan, O., Galeotti, J., Esparza, S., Hussaini, M., van Deventer, H. W., Foster, M. C., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26110 · Cited by 30
Chen, X., Othus, M. K. D., Wood, B. L., Walter, R. B., Becker, P. S., Percival, M. M., Abkowitz, J. L., Appelbaum, F. R., & Estey, E. H. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1861267 · Cited by 29
Self-citationGermline Predisposition to Hematolymphoid Neoplasia
Weinberg, O. K., Kuo, F. C., & Calvo, K. R. (2019) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz067 · Cited by 27
Ferrara, F., & Picardi, A. (2019) · Cancers · doi:10.3390/cancers12010059 · Cited by 27
Fang, H., Yabe, M., Zhang, X., Kim, Y., Wu, X., Wei, P., Chi, S., Zheng, L., Garcia‐Manero, G., Shao, L., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00741-w · Cited by 24
Time to blur the blast boundaries
Dinardo, C. D., Garcia‐Manero, G., & Kantarjian, H. M. (2022) · Cancer · doi:10.1002/cncr.34119 · Cited by 20
Self-citationToth, L. N., GREEN, D. P., Peterson, J. D., Deharvengt, S. J., Abreu, F. B. D., & Loo, E. Y. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1587757 · Cited by 7
Cited by
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
DiNardo, C. D., Erba, H. P., Freeman, S. D., & Wei, A. H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00108-3 · Cited by 437
Self-citationErba, H. P., Montesinos, P., Kim, H.-J., Patkowska, E., Vrhovac, R., Žák, P., Wang, P.-N., Mitov, T., Hanyok, J., Kamel, Y. M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00464-6 · Cited by 418
Self-citationCAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Clonal haematopoiesis and dysregulation of the immune system
Belizaire, R., Wong, W. J., Robinette, M. L., & Ebert, B. L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00843-3 · Cited by 161
Self-citation
Metadata
- Authors
- Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Miyazaki, Y., Niederwieser, D., Ossenkoppele, G., Röllig, C., Sierra, J., Stein, E. M., Tallman, M. S., Tien, H.-F., Wang, J., Wierzbowska, A., & Löwenberg, B.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2022-09-22
- Volume
- 140
- Issue
- 12
- Pages
- 1345-1377
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4284884567
- Cited by
- 3,279
- References
- 183
- FWCI
- 393.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.